-DOCSTART- -X- O
There -X- _ O
is -X- _ O
a -X- _ O
lack -X- _ O
of -X- _ O
definitive -X- _ O
data -X- _ O
on -X- _ O
the -X- _ O
effective -X- _ O
management -X- _ O
of -X- _ O
acute -X- _ B-Patient
respiratory -X- _ I-Patient
distress -X- _ I-Patient
syndrome -X- _ I-Patient
( -X- _ I-Patient
ARDS -X- _ I-Patient
) -X- _ I-Patient
in -X- _ I-Patient
infants -X- _ I-Patient
and -X- _ I-Patient
children. -X- _ I-Patient
The -X- _ O
development -X- _ O
and -X- _ O
validation -X- _ O
of -X- _ O
the -X- _ O
Berlin -X- _ O
definition -X- _ O
( -X- _ O
BD -X- _ O
) -X- _ O
for -X- _ O
ARDS -X- _ O
and -X- _ O
the -X- _ O
Pediatric -X- _ O
Acute -X- _ O
Lung -X- _ O
Injury -X- _ O
Consensus -X- _ O
Conference -X- _ O
( -X- _ O
PALICC -X- _ O
) -X- _ O
recommendations -X- _ O
in -X- _ O
children -X- _ O
represented -X- _ O
a -X- _ O
major -X- _ O
advance -X- _ O
in -X- _ O
optimizing -X- _ O
research -X- _ O
and -X- _ O
treatment -X- _ O
, -X- _ O
mainly -X- _ O
due -X- _ O
to -X- _ O
the -X- _ O
introduction -X- _ O
of -X- _ O
a -X- _ O
severe -X- _ O
ARDS -X- _ O
category. -X- _ O
Proposed -X- _ O
reasons -X- _ O
for -X- _ O
the -X- _ O
lack -X- _ O
of -X- _ O
consistent -X- _ O
results -X- _ O
with -X- _ O
surfactants -X- _ B-Intervention
in -X- _ O
children -X- _ O
and -X- _ O
infants -X- _ O
compared -X- _ O
with -X- _ O
neonates -X- _ B-Comparison
include -X- _ O
different -X- _ B-Intervention
causes -X- _ I-Intervention
, -X- _ O
type -X- _ B-Intervention
of -X- _ I-Intervention
lung -X- _ I-Intervention
damage -X- _ I-Intervention
( -X- _ I-Intervention
direct -X- _ I-Intervention
or -X- _ I-Intervention
indirect -X- _ I-Intervention
) -X- _ I-Intervention
, -X- _ O
timing -X- _ B-Intervention
and -X- _ I-Intervention
mode -X- _ I-Intervention
of -X- _ I-Intervention
administration -X- _ I-Intervention
as -X- _ I-Intervention
well -X- _ I-Intervention
as -X- _ I-Intervention
the -X- _ I-Intervention
type -X- _ I-Intervention
of -X- _ I-Intervention
surfactant -X- _ I-Intervention
used. -X- _ I-Intervention
Secretory -X- _ O
phospholipase -X- _ O
A2 -X- _ O
plays -X- _ O
an -X- _ O
important -X- _ O
role -X- _ O
in -X- _ O
inflammation -X- _ O
and -X- _ O
possible -X- _ O
dysfunction -X- _ O
of -X- _ O
surfactants -X- _ B-Intervention
in -X- _ O
ARDS. -X- _ O
Bronchoalveolar -X- _ B-Outcome
lavage -X- _ I-Outcome
( -X- _ I-Outcome
BAL -X- _ I-Outcome
) -X- _ I-Outcome
with -X- _ I-Outcome
normal -X- _ I-Outcome
saline -X- _ I-Outcome
and -X- _ I-Outcome
surfactant -X- _ I-Outcome
allows -X- _ I-Outcome
the -X- _ I-Outcome
removal -X- _ I-Outcome
of -X- _ I-Outcome
inhaled -X- _ I-Outcome
material -X- _ I-Outcome
, -X- _ I-Outcome
the -X- _ I-Outcome
recruitment -X- _ I-Outcome
of -X- _ I-Outcome
non-ventilating -X- _ I-Outcome
areas -X- _ I-Outcome
and -X- _ I-Outcome
the -X- _ I-Outcome
maintenance -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
surfactant -X- _ I-Outcome
pool -X- _ I-Outcome
size. -X- _ I-Outcome
BAL -X- _ I-Outcome
with -X- _ I-Outcome
diluted -X- _ I-Outcome
surfactant -X- _ I-Outcome
allows -X- _ I-Outcome
rapid -X- _ I-Outcome
absorption -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
surfactant -X- _ I-Outcome
at -X- _ I-Outcome
the -X- _ I-Outcome
air -X- _ I-Outcome
/ -X- _ I-Outcome
liquid -X- _ I-Outcome
interface -X- _ I-Outcome
, -X- _ I-Outcome
which -X- _ I-Outcome
blocks -X- _ I-Outcome
the -X- _ I-Outcome
progression -X- _ I-Outcome
of -X- _ I-Outcome
pathological -X- _ I-Outcome
lung -X- _ I-Outcome
disease -X- _ I-Outcome
and -X- _ I-Outcome
in -X- _ I-Outcome
turn -X- _ I-Outcome
disrupts -X- _ I-Outcome
the -X- _ I-Outcome
inflammatory -X- _ I-Outcome
cycle. -X- _ I-Outcome
Importantly -X- _ I-Outcome
, -X- _ I-Outcome
it -X- _ I-Outcome
is -X- _ I-Outcome
now -X- _ I-Outcome
recognized -X- _ I-Outcome
that -X- _ I-Outcome
the -X- _ I-Outcome
type -X- _ I-Outcome
of -X- _ I-Outcome
surfactant -X- _ I-Outcome
, -X- _ I-Outcome
the -X- _ I-Outcome
time -X- _ I-Outcome
of -X- _ I-Outcome
administration -X- _ I-Outcome
and -X- _ I-Outcome
the -X- _ I-Outcome
method -X- _ I-Outcome
of -X- _ I-Outcome
administration -X- _ I-Outcome
could -X- _ I-Outcome
all -X- _ I-Outcome
play -X- _ I-Outcome
an -X- _ I-Outcome
important -X- _ I-Outcome
role -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
management -X- _ I-Outcome
of -X- _ I-Outcome
ARDS -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
there -X- _ I-Outcome
is -X- _ I-Outcome
evidence -X- _ I-Outcome
that -X- _ I-Outcome
surfactant -X- _ I-Outcome
is -X- _ I-Outcome
effective -X- _ I-Outcome
and -X- _ I-Outcome
well -X- _ I-Outcome
tolerated -X- _ I-Outcome
in -X- _ I-Outcome
children -X- _ I-Outcome
and -X- _ I-Outcome
infants -X- _ I-Outcome
with -X- _ I-Outcome
ARDS -X- _ I-Outcome
. -X- _ O

